In a scathing rebuke (PDF) to AstraZeneca, the FDA cited “critical data quality issues that affect key analyses, including the primary endpoint” within a dataset for Saphnelo (anifrolumab) for the ...

AstraZeneca’s latest fair value estimate has been set at £162.67, up from £152.79, marking a modest uplift in the central value per share that many investors track closely. That shift lines up with ...

The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and ...

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma ...

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space. The ...

Consumers will have to wait longer for a more affordable diabetes and heart failure drug after pharmaceutical giant ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...

AstraZeneca PLC closed 0.08% below its 52-week high of £155.54, which the company achieved on February 24th.